FAQ

ADL5859

Known as: ADL 5859, ADL-5859 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
0120082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development.
INTRODUCTION Opioids are widely used to treat severe pain. Most clinically used opioids activate µ-opioid receptors (MOR). Their… (More)
Is this relevant?
2016
2016
Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.
Kappa opioid (KOP) receptor antagonists and delta opioid (DOP) receptor agonists have antidepressant-like effects in animal tests… (More)
Is this relevant?
2015
2015
Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures.
The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat… (More)
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
In vivo properties of KNT-127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice.
BACKGROUND AND PURPOSE Activation of δ opioid (DOP) receptors regulates pain and emotional responses, and also displays ligand… (More)
Is this relevant?
2013
2013
Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling.
Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization.
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4… (More)
Is this relevant?
2009
2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents… (More)
Is this relevant?
2008
2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain… (More)
Is this relevant?